Mammallian cell culture process for protein production

a cell culture and protein technology, applied in the field of mammalian cell culture methods and processes, can solve the problems of affecting the immunogenicity and clearance rate of products, affecting the run time of cell culture processes, and reducing the viability of cells, so as to achieve the effect of increasing cell viability

Inactive Publication Date: 2012-01-19
BRISTOL MYERS SQUIBB CO
View PDF6 Cites 51 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]The present invention provides new processes for the production of proteins, preferably recombinant protein products, more preferably glycoprotein products, by animal or mammalian cell cultures. These new processes achieve increased cell viability.
[0016]One aspect of this invention concerns the use two or more temperature shifts. In this aspect, cell culture processes of this invention can advantageously achieve an enhanced final titer or concentration of product, e.g., glycoprotein, as well as an enhanced sialic acid content of the glycoprotein produced by the cultured cells. More specifically, in accordance with this invention, two or more temperature shifts during the cell culturing period sustain a high cell viability of the cells in the culture and can provide a high quantity and quality of produced product throughout an entire culture run. Also, according to one aspect of the invention, the two or more temperature shifts comprising the culturing processes can advantageously allow for an extension of the production phase of the culture. During the extended production phase, the titer of the desired product is increased; the product quality, as characterized by sialic acid content, is maintained at a high level; and cell viability is also maintained at a high level. In addition, the extended production phase associated with the culturing processes of the invention allows for the production of product beyond that which is produced during a standard production phase.
[0017]In one aspect of the present invention, multi-step temperature shifts, preferably, timed multi-step temperature shifts comprising two or more downward temperature shifts, are used in the culturing of mammalian cells to produce a desired protein product, particularly, a glycoprotein product. Two or more (i.e., at least two) temperature shifts, which may be performed after the growth phase of the culture, comprise the processes of this invention. With the at least two temperature shifts, preferably with approximately four day increments between the shifts, a high protein yield with a concomitant high sialic acid content of the desired protein product can be achieved. The multiple temperature shifts comprising the culturing methods can achieve both high quality and quantity of protein product, as well as sustain cell viability for the duration of a culturing period.

Problems solved by technology

However, bacterial and yeast cells are limited in their ability to optimally express high molecular weight protein products, to properly fold a protein having a complex steric structure, and / or to provide the necessary post-translational modifications to mature an expressed glycoprotein, thereby affecting the immunogenicity and clearance rate of the product.
Run times of cell culture processes, particularly non-continuous processes, are usually limited by the remaining viability of the cells, which typically declines over the course of the run.
The presence of cell debris and the contents of dead cells in the culture can negatively impact on the ability to isolate and / or purify the protein product at the end of the culturing run.
However, suramin did not protect against apoptosis during the death phase.
As a result, suramin was capable of maintaining high viability during the growth phase, but did not allow for an extension of culture longevity.
Moreover, it has never been reported that dextran sulfate can delay the onset of the death phase, extend the growth phase, or arrest the death phase.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mammallian cell culture process for protein production
  • Mammallian cell culture process for protein production
  • Mammallian cell culture process for protein production

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0170]This Example provides materials and reagents employed in the processes of the present invention for the culturing of recombinant cells that produce the exemplified CTLA4Ig fusion proteins as described herein in Examples 2-4.

1. Cell Culture Medium

[0171]The basal cell culture medium used for all phases of cell inoculum generation and for growth of cultures in bioreactors, including 5 liter (5 L) and 50 liter (50 L) production reactors, was modified CD-CHO medium containing glutamine, sodium bicarbonate, insulin and methotrexate (Invitrogen, Carlsbad, Calif.), as exemplified in Table 1. The pH of the medium was adjusted to 7.0 with 1 N HCl.

TABLE 1Modified CD-CHOMedium ComponentConcentrationCD-CHO 25x Acids I40ml / L(Invitrogen, Carlsbad, CA)CD-CHO 25x Acids II40ml / L(Invitrogen, Carlsbad, CA)CD-CHO 25x Salts I40ml / L(Invitrogen, Carlsbad, CA)CD-CHO 25x Salts II40ml / L(Invitrogen, Carlsbad, CA)L-glutamine0.585g / L(Invitrogen)r-human insulin0.1ml / L(10 mg / mL)(Invitrogen)Methotrexate5μl / L(...

example 2

[0177]This Example describes the production of CTLA4Ig, shown as −1 to 357 or +1 to 357 in FIG. 3, (encoding DNA deposited as ATCC 68629), from cultured CHO cells.

[0178]This Example also describes a process of this invention for producing both high quantity and high quality CTLA4Ig protein, involving culture runs having two- or three-step temperature shifts and total run times of 14, 21, or 28-30 days. A temperature shift (T-shift) from 37° C. to 34° C. occurred on day 6 (end of logarithmic growth phase) and a second T-shift from 34° C. to 32° C. occurred on day 10. The run was ended on day 14, day 21, or day 28, and for the two-step shift, the temperature was controlled at 32° C. from the shift on day 10 until the end of the run. For the three-step shift, the temperature was controlled at 30° C. from the day of the shift until the end of the run The processes described resulted in increased end titer of protein product, increased end cell viability, and volumetric productivity, com...

example 3

[0183]This Example describes and presents the results of comparative evaluations to assess various culturing procedures, including the multi-step culturing methods performed in accordance with the present invention. The end titer (in g / L) of glycoprotein product was determined, as were the end titer sialic acid content of the protein, the cell viability at the end of the runs (end cell viability) and the cell density at the end of the runs (viable end cell density).

[0184]Experiments I-A, I-B and I-C; II-A, II-B and II-C; and III-A, III-B and III-C refer to the same cell culture run with the same temperature shift profile assessed at different times, i.e., for I-A, II-A, and III-A, the product and cell parameters were assessed after 14 days, for I-B, II-B and III-B after 21 days, and for I-C, II-C and III-C after 28 days. These experiments were performed in a 5 L bioreactor in which the culture conditions were controlled as follows: pH at 7.0; dissolved oxygen at 40%; agitation at 60...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. Throughout their duration, the culturing processes of the invention involving two or more downward shifts in temperature sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein. In another aspect, the methods comprise the delayed addition of polyanionic compound during the culturing period. The delayed addition of polyanionic compound sustains a high viability of the cultured cells, and can extend the growth phase, delay the onset of the death phase, and arrest the death phase.

Description

[0001]This invention claims priority from provisional U.S. application Ser. No. 60 / 436,101 filed Dec. 23, 2002, which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to new methods and processes for culturing mammalian cells which produce a protein product, preferably a glycosylated protein product. Performance of the cell culturing methods and processes result in high cell viability and can also result in high product quality and quantity, extension of the growth phase, delay of onset of the death phase, and arrest of the death phase.BACKGROUND OF THE INVENTION[0003]Animal cell culture, notably mammalian cell culture, is preferably used for the expression of recombinantly produced, glycosylated proteins for therapeutic and / or prophylactic applications. Glycosylation patterns of recombinant glycoproteins are important, because the oligosaccharide side chains of glycoproteins affect protein function, as well as the intramo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/10C07K14/705C12N5/00C12N5/02C12P21/00
CPCC07K14/70521C12N5/0018C12N2500/34C12N2500/74C12P21/005C12N2501/90C12N2501/905C12N2501/91C12N2510/02C12N2501/33C12N5/00C07K14/47
Inventor SCHILLING, BERNHARD M.MATLOCK, LINDAZEGARELLI, STEPHEN G.BURNETT, WILLIAM V.JOOSTEN, CHRISTOPH E.BASCH, JONATHAN D.SAKHAMURI, SIVAKESAVALEE, STEVEN S.
Owner BRISTOL MYERS SQUIBB CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products